Abstract

A plasmalogen production–promoting culture medium according to the present invention includes lactose as a carbon source and is to be used to culture lactic acid bacteria.

IPC Classes  ?

• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen
• C12N 1/20 - Bacteria; Culture media therefor
• C12P 7/6427 - Polyunsaturated fatty acids [PUFA], i.e. having two or more double bonds in their backbone

Abstract

Provided is an antifibrotic agent comprising a copolymer having a constituent unit (a) containing an N-acetylglucosamine group and a constituent unit (b) containing a structure represented by general formula (b) (excluding a constituent corresponding to the constituent unit (a)). In general formula (b), Yb represents a bivalent linking group containing an oxygen atom; Rb represents a hydrogen atom or an organic group; and * represents a bonding hand.

IPC Classes  ?

• A61K 31/795 - Polymers containing sulfur
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C08F 20/36 - Esters containing nitrogen containing oxygen in addition to the carboxy oxygen

Abstract

The present invention relates to a method for preparing a double-stranded DNA library from single-stranded DNA fragments and provides a highly efficient library preparation method, etc., that generates or contains few adapter dimers. The present invention is a method for preparing a double-stranded DNA library from single-stranded DNA fragments that includes the specific steps (i) to (v).

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/6869 - Methods for sequencing
• C40B 40/06 - Libraries containing nucleotides or polynucleotides, or derivatives thereof

Abstract

A heat transfer member (1) comprises: a base material (2) that comprises an inorganic compound containing a metallic element or a metal; and an oxide layer (3) that comprises an oxide of the metallic element contained in the base material (2) and that is formed on the base material (2). The oxide layer (3) has a plurality of pores (31) each provided with: a first part (312) which has an opening (311) in a surface of the heat transfer member (1) and in which the average opening diameter of the opening (311) is 5-70 nm; and a second part (313) which is connected to the first part (312) and in which the average pore diameter is greater than the average opening diameter of the first part (312). The average depth of the second part (313) is not less than 600 nm and not more than 20 μm.

IPC Classes  ?

• C25D 11/12 - Anodising more than once, e.g. in different baths
• C25D 11/04 - Anodisation of aluminium or alloys based thereon
• F28F 13/02 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by influencing fluid boundary
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes

Abstract

Provided is a carbonyl sulfide production method that can produce carbonyl sulfide with a good yield using a gas-phase flow method and without using a catalyst. This method for producing carbonyl sulfide comprises: a step for exciting, in hot plasma, a crude gas comprising a starting substance containing carbon atoms, sulfur atoms, and oxygen atoms; and a step for cooling the crude gas excited by plasma.

IPC Classes  ?

• C01B 32/77 - Carbon oxysulfide

Abstract

A method according to the present invention is a method for predicting the therapeutic effect of pharmacotherapy in the treatment of a subject with metastatic prostate cancer, wherein the pharmacotherapy includes at least one selected from among androgen deprivation therapy, androgen receptor deprivation therapy, and an anticancer drug, and said method includes a step for detecting the presence or absence of at least one single nucleotide polymorphism in the subject.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/4166 - 1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 35/04 - Antineoplastic agents specific for metastasis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6876 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes

Abstract

Provided are: a bipolar membrane electrodialyzer which has a high electric-current efficiency and in which the cation-exchange membrane is inhibited from suffering scale deposition therein due to divalent cations; and a method for operating the bipolar membrane electrodialyzer.　The method is for operating a bipolar membrane electrodialyzer configured of a bipolar membrane, a cation-exchange membrane, and an anion-exchange membrane, the method comprising using the bipolar membrane electrodialyzer to yield an acid and an alkali from brine and being characterized by conducting electrodialysis while regulating the acid solution and/or the alkali solution so as to contain a salt to be decomposed.

IPC Classes  ?

• C02F 1/469 - Treatment of water, waste water, or sewage by electrochemical methods by electrochemical separation, e.g. by electro-osmosis, electrodialysis, electrophoresis
• B01D 61/44 - Ion-selective electrodialysis
• B01D 61/46 - Apparatus therefor

Abstract

Provided are a production method and a production system of calcium carbonate that utilize a calcium-containing waste and can control the alkali content in the obtained calcium carbonate.　The calcium carbonate production method for producing calcium carbonate from a calcium-containing waste includes: a calcium dissolution step for adding an aqueous hydrochloric acid solution to the calcium-containing waste and dissolving calcium to prepare an aqueous solution containing calcium ions; a separation step for adjusting the hydrogen ion concentration index of the aqueous solution containing calcium ions to separate Mg, etc. from the aqueous solution; and a calcium carbonate preparation step for adding an aqueous solution containing potassium carbonate and/or sodium carbonate to the aqueous solution containing calcium ions obtained in the separation step and reacting to prepare calcium carbonate. In this calcium carbonate production method (system), in the calcium carbonate preparation step, the rate of the addition of the aqueous solution containing potassium carbonate and/or sodium carbonate is controlled so as to adjust κ, which is represented by a specific formula, to 3000 or less.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation

Abstract

The present invention provides candidate molecules for constituent components of various lipid nanoparticles.　The present invention pertains to a C-glycoside glycolipid compound represented by formula (I) or formula (II), a lipid nanoparticle containing the same, and a pharmaceutical composition containing the lipid nanoparticles, particularly a vaccine.

IPC Classes  ?

• C07D 309/10 - Oxygen atoms
• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 37/04 - Immunostimulants
• C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

This protein comprises an amino acid sequence selected from the group consisting of amino acid sequences (a), (b), (c) and (d) and has a plasmalogen synthesis activity in a bacterium that expresses the protein. (a) The amino acid sequence represented by SEQ ID NO:1; (b) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:1; (c) the amino acid sequence represented by SEQ ID NO:2; and (d) an amino acid sequence which has 80% or higher sequence identity with the amino acid sequence represented by SEQ ID NO:2.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/31 - Genes encoding microbial proteins, e.g. enterotoxins
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12P 7/64 - Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats

Abstract

Provided are an introduction device and a delivery method that are applicable to various types of cells and capable of delivering a target substance, even including a large molecule, to cells at a high efficiency. The introduction device and the method for delivering a target substance to cells using the introduction device, said introduction device being equipped with a bubble generation unit 20, a counter electrode 40 and a power supply unit 50 connected respectively to the bubble generation unit and the counter electrode. The bubble generation unit 50 comprises a core material 21 made of a conductive material and forming an active electrode, and a tubular member 22 made of an insulating material and extending along the core material to cover around the core material. The tip of the tubular member 22 is substantially on the same plane as the tip of the core material 21, or extends beyond the tip of the core material 21. The bubble generation unit 20 is configured to generate bubbles from the tip of the bubble generation unit 20 when a voltage is applied to the active electrode from the power supply unit in the state where the tip of the bubble generation unit 20 and the counter electrode 40 are in contact with a liquid containing the cells and the target substance.

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 15/09 - Recombinant DNA-technology

Abstract

Provided is a drug for preventing or treating heart failure, that is effective and that does not have a blood pressure lowering effect.　The present invention pertains to: a pharmaceutical composition for preventing or treating heart failure or skeletal muscle failure, the pharmaceutical composition containing a TRPC3/6/7 channel activator; and a related screening method.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/05 - Phenols
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• C07D 401/00 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

The present invention relates to a compound represented by formula (I) (in the formula, R1is a C1-4 alkyl group or the like, and A1and A2are each independently a group, etc. represented by formula (II), in which R2and R3 are each independently a hydrogen atom, a C1-4 alkyl group, or the like, and * is a bonded section), a light-emitting material containing said compound, and a light-emitting element containing said light-emitting material.

IPC Classes  ?

• C07F 5/02 - Boron compounds
• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 50/10 - OLEDs or polymer light-emitting diodes [PLED]

Abstract

The present invention provides a compound for treating or preventing reduced intracellular ATP levels.　The present invention relates to a compound represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutical composition that contains the compound or the pharmaceutically acceptable salt or solvate thereof. [In the formula, X and Y are the same or different and are each selected from among substituent group A, which is groups represented by formula 1: -O-R1 (in the formula, R1 is selected from among hydrogen, C1–8 alkyl groups, C1–3 alkyl aryl groups, CH3OCH2-, CH3OCH2CH2-, ester groups, phenyl groups, pyridyl groups, benzyl groups, indolyl groups, and naphthyl groups, and any aromatic rings or heterocyclic rings may be substituted with one to three functional groups) when the atom connected to the phosphorus atom is O, or substituent group B, which is groups represented by formula 2: -R2-R3 (in the formula, R2 is a residue generally described as an amino carboxylic acid, and R3 is a substituent bonded to the carboxylic acid portion of the amino carboxylic acid of R2) when the atom connected to the phosphorus atom is N.]

IPC Classes  ?

• C07H 19/207 - Purine radicals with the saccharide radical being esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine-adenine dinucleotide or nicotinamide-adenine dinucleotide
• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 25/02 - Drugs for disorders of the nervous system for peripheral neuropathies
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07F 9/6558 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system

Abstract

123411 represents triphenyl phosphine, pyridine, imidazole, dimethyl sulfoxide or water; X represents a monovalent group that is obtained by removing a hydrogen atom from a carboxyl group of a carboxylic acid; X- represents an anion of the carboxylic acid; and n represents 1 or 2.

IPC Classes  ?

• C07F 15/00 - Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic System
• B01J 31/24 - Phosphines
• B01J 37/04 - Mixing
• C07C 45/28 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by oxidation of —CHx-moieties
• C07C 49/403 - Saturated compounds containing a keto group being part of a ring of a six-membered ring
• C07C 67/29 - Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by introduction of oxygen-containing functional groups
• C07C 69/14 - Acetic acid esters of monohydroxylic compounds
• C07C 69/16 - Acetic acid esters of dihydroxylic compounds
• C07C 69/78 - Benzoic acid esters
• C07C 201/12 - Preparation of nitro compounds by reactions not involving the formation of nitro groups
• C07C 205/57 - Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07C 227/16 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
• C07C 229/08 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
• C07C 303/40 - Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
• C07C 311/19 - Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
• C07D 213/38 - Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
• C07B 61/00 - Other general methods

Abstract

Provided is a novel polymer compound containing a chain ether structure and exhibiting bioaffinity.　The polymer compound has a polyolefin skeleton as a main chain and a structure including a chain ether structure introduced into a side chain part thereof.

IPC Classes  ?

• C08F 8/02 - Alkylation
• C08F 16/16 - Monomers containing no hetero atoms other than the ether oxygen
• C09D 129/10 - Homopolymers or copolymers of unsaturated ethers

Abstract

This flotation recovery rate prediction device, for predicting the recovery rate of a metal subject to sorting in flotation sorting in which the metal subject to sorting is separated from an ore in which a plurality of ores containing a plurality of minerals are mixed, comprises: a receiving unit for receiving a desired recovery rate of the metal subject to sorting; an acquisition unit for acquiring information representing the relationship between soluble metal ratio and mineral content, and information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores; a calculation unit for calculating, on the basis of the information representing the relationship between soluble metal ratio and mineral content and the information representing the recovery rate of the metal subject to sorting and the mineral content of each of the ores, the mixing ratio of the ores to achieve the desired recovery rate of the metal subject to sorting; and an output unit for outputting information indicating the calculated mixing ratio of the ores.

IPC Classes  ?

• E21C 41/22 - Methods of underground mining; Layouts therefor for ores, e.g. mining placers

Abstract

The present invention provides a copolymer compound having a new property through compounding a polymer comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton with a structure different from the primary structure of the polymer.　Provided is a polymer compound comprising a (meth)acrylic skeleton and/or a (meth)acrylamide skeleton, wherein a side chain comprising a phosphonic acid group is introduced as a part of a side chain of the polymer compound.

IPC Classes  ?

• C08F 220/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 220/10 - Esters
• C08F 220/56 - Acrylamide; Methacrylamide
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08F 230/02 - Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and containing phosphorus, selenium, tellurium, or a metal containing phosphorus
• C08L 33/04 - Homopolymers or copolymers of esters
• C08L 33/24 - Homopolymers or copolymers of amides or imides
• C08L 43/02 - Homopolymers or copolymers of monomers containing phosphorus
• C09D 133/04 - Homopolymers or copolymers of esters
• C09D 133/24 - Homopolymers or copolymers of amides or imides
• C09D 143/02 - Homopolymers or copolymers of monomers containing phosphorus

Abstract

The subject's brain neurogenesis promoter of the present invention contains miR-30a, etc. or a vector which is for expressing miR-30a, etc. in the brain nerves of young and elderly subjects. The present invention also provides an agent for improving higher nervous function, an agent for improving memory learning function, a method for promoting brain neurogenesis, a method for improving higher nervous function, and a method for improving memory learning function. In the subject's brain neurogenesis promoter, etc. of the present invention, the subject may be an elderly subject.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 35/76 - Viruses; Subviral particles; Bacteriophages
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention provides a composition to be used for attenuating skin barrier, said composition containing an anionic long-chain lipid (in particular, a long-chain fatty acid). The present invention provides a dispersion in which a complex (for example, a solid complex) comprising a cationic long-chain lipid, an anionic long-chain lipid and a drug is dispersed.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/08 - Solutions
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 17/00 - Drugs for dermatological disorders
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The purpose of the present invention is to provide a low-production-cost and low-loss optical element. Provided are an optical element (100) and a method for producing the optical element (100), the optical element (100) having a core (2) and a cladding comprising an undercladding (4) and an overcladding (3) on a substrate (1), wherein the core (2) includes a membrane structure (21) in at least a leading end region (31), includes a thin line structure (22) in an inner portion away from a leading end (P1) of the membrane structure (21) in a length direction, and has a stacking region (32) in which the membrane structure (21) and the thin line structure (22) overlap adjacent to each other in a thickness direction, a width (W1) at the leading end (P1) of the membrane structure (21) is wider than the width in the stacking region (32) of the thin line structure (22), and the materials of the membrane structure (21) and the thin line structure (22) included in the core (2) have substantially the same refractive index.

IPC Classes  ?

• G02B 6/122 - Basic optical elements, e.g. light-guiding paths
• G02B 6/13 - Integrated optical circuits characterised by the manufacturing method
• G02B 6/30 - Optical coupling means for use between fibre and thin-film device

Abstract

This composite conductive material includes: a main phase that includes a crystalline phase having a double perovskite crystalline structure; and particles that each project from the surface of the main phase and that each contain an oxide of a metal element occupying the B site of the crystalline phase.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• C01G 51/00 - Compounds of cobalt
• C01G 53/00 - Compounds of nickel
• H01B 1/06 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances
• H01B 1/08 - Conductors or conductive bodies characterised by the conductive materials; Selection of materials as conductors mainly consisting of other non-metallic substances oxides
• H01M 4/88 - Processes of manufacture
• H01M 8/12 - Fuel cells with solid electrolytes operating at high temperature, e.g. with stabilised ZrO2 electrolyte

Abstract

An oral vaccine composition against a porcine circovirus-related disease, the oral vaccine composition comprising a pupa or a cell of a baculovirus infectious insect that has been subjected to an infection treatment with a recombinant baculovirus into which a DNA encoding a porcine circovirus type 2 protein has been introduced and subjected to a freeze-drying treatment.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 31/20 - Antivirals for DNA viruses
• A61P 37/04 - Immunostimulants
• A61P 17/00 - Drugs for dermatological disorders
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/34 - Proteins from DNA viruses
• C12N 15/86 - Viral vectors
• C12N 15/866 - Baculoviral vectors
• A61K 38/02 - Peptides of undefined number of amino acids; Derivatives thereof
• A61K 35/64 - Insects, e.g. bees, wasps or fleas

Abstract

Provided is, for example, a DNA methyltransferase that can recognize and methylate a short context other than a CG dinucleotide sequence in which endogenous methylation occurs, the short context being comparable to the CG dinucleotide sequence. The present invention pertains to a protein or the like in which some amino acid residues including the N terminal of a DNA methyltransferase of M.CviQIX or M.CviPII have been deleted, and activity of specifically recognizing a CC dinucleotide sequence and 5-methylating a cytosine residue of the 5' side in the sequence is acquired.

IPC Classes  ?

• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 1/15 - Fungi ; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/19 - Yeasts; Culture media therefor modified by introduction of foreign genetic material
• C12N 1/21 - Bacteria; Culture media therefor modified by introduction of foreign genetic material
• C12N 15/54 - Transferases (2)
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• C12N 9/10 - Transferases (2.)

Abstract

Provided is a plant sensor device that is capable of suppressing the influence of outside light in the surrounding environment to quantify the growth degree of a plant and obtaining a parameter related to the amount of foliage of the plant using a simple and low-cost configuration. A plant sensor device 100 comprising a light source 11 that intermittently irradiates a plant with near-infrared (NIR) light, a radiation sensor 21 that is disposed on the opposite side of the light source 11 with respect to the plant and outputs output values obtained by photoelectrical conversion of the received transmitted NIR light having transmitted through the plant, and a recording unit 31 that records the output values from the radiation sensor 21, wherein the recording unit 31 records the irradiation period and the quenching period of the near-infrared light at light source 11, and the recording unit 31 classifies the output values from the radiation sensor into (1) NIR output values during the irradiation period of the near-infrared light and (2) non-irradiation output values during the quenching period of the near-infrared light; and an active optical measurement method of plant.

IPC Classes  ?

• A01G 7/00 - Botany in general

Abstract

The present disclosure addresses the problem of providing at least a technology for enhancing the expression of SIRT3 genes. Said problem is solved by a composition for enhancing SIRT3 gene expression, the composition containing urolithin M3 as an active ingredient.

IPC Classes  ?

• A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61P 17/18 - Antioxidants, e.g. antiradicals
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 27/16 - Otologicals
• A61P 39/06 - Free radical scavengers or antioxidants
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/08 - Anti-ageing preparations
• C12N 15/12 - Genes encoding animal proteins
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention addresses the problem of providing a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β. The present invention relates to an IL-6 and/or IL-1β inhibitor comprising a compound represented by formula (I) (in the formula, each symbol is as described in the specification.) or a pharmaceutically acceptable salt thereof. The present invention also relates to a medicine for treating cardiovascular disease associated with inflammation of the cardiovascular system related to IL-6 and/or IL-1β that contains as an active ingredient the abovementioned compound or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/10 - Antioedematous agents; Diuretics
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 9/12 - Antihypertensives
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This disease state assessment kit for Rett syndrome comprises a reagent for detecting a gene contained in the mitochondrial genome in a sample collected from a subject.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The purpose of the present invention is to provide a novel composition for improving brain function and a novel composition for promoting the production of brain-derived neurotrophic factor (BDNF). The present invention provides a composition for maintaining and/or improving brain function that contains isovaleraldehyde as an active ingredient. The present invention also provides a composition for promoting the production of brain-derived neurotrophic factor (BDNF) that contains isovaleraldehyde as an active ingredient. The aforesaid compositions are preferably food compositions, feed compositions or pharmaceutical compositions.

IPC Classes  ?

• A23L 33/105 - Plant extracts, their artificial duplicates or their derivatives
• A23K 20/105 - Aliphatic or alicyclic compounds
• A61K 31/11 - Aldehydes
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/12 - Genes encoding animal proteins

Abstract

This blast state evaluation device evaluates the blast rate after a blast treatment on a surface to be examined of a structure, the device including: an irradiation unit 11 that irradiates the surface to be examined with measurement light; a detection unit 12 that detects reflected light from the surface to be examined that has been irradiated with the measurement light; and an evaluation unit 22 serving as an analysis unit that estimates the blast rate on the surface to be examined on the basis of the intensity of light of a specific wavelength included in the reflected light detected at the detection unit 12.

IPC Classes  ?

• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01B 11/30 - Measuring arrangements characterised by the use of optical techniques for measuring roughness or irregularity of surfaces

Abstract

722Fe particles and the like.

IPC Classes  ?

• C22C 21/10 - Alloys based on aluminium with zinc as the next major constituent
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/04 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon

Abstract

The present invention improves the physical properties of a polymer that includes an alkoxy alkyl (meth)acrylate as a principal structural unit to achieve a polymer that has physical properties that are very similar to a biological substance. The present invention provides a copolymer that includes as structural units (A) a hydroxy alkyl (meth)acrylate and/or an alkoxy alkyl (meth)acrylate and (B) a monomer that has a host group.

IPC Classes  ?

• C08F 220/22 - Esters containing halogen
• C08F 220/26 - Esters containing oxygen in addition to the carboxy oxygen
• C08F 220/28 - Esters containing oxygen in addition to the carboxy oxygen containing no aromatic rings in the alcohol moiety
• C08F 220/58 - Amides containing oxygen in addition to the carbonamido oxygen
• C08L 33/14 - Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
• C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
• A61L 27/16 - Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/20 - Polysaccharides
• A61L 27/50 - Materials characterised by their function or physical properties

Abstract

The present invention addresses the problem of clarifying the relation between environmental stress and seed quality and improving the yield and quality of a crop seed by a new method different from conventional gene engineering methods. Provided are: a plant seed having a promotor in which the methylation level of any gene selected from the group consisting of gene SLB1, gene Hd1, gene AGPS2b, gene GBSSI, gene SuSy2, gene AMy1A, and gene Amy3D is effectively controlled, and a product of the plant seed; and a harvest obtained therefrom and a processed product of the harvest. Also provided is a method for producing a plant seed having useful characteristics, the production method involving: a step for culturing a first generation plant under environmental stress; and a step for obtaining, from the cultured plant or an offspring thereof, a seed memorizing the environmental stress.

IPC Classes  ?

• A01H 3/00 - Processes for modifying phenotypes
• A01H 5/10 - Seeds
• C12N 15/09 - Recombinant DNA-technology
• A01G 7/00 - Botany in general
• A01H 6/46 - Gramineae or Poaceae, e.g. ryegrass, rice, wheat or maize

Abstract

Provided is a polymer composition that exhibits sufficient biocompatibility and is capable of suppressing the elastic modulus, which is the source of elastic force that is generated by deformation.　Provided is a polymer composition containing a polymer that has a (meth)acrylate backbone and that contains, at the side chain segment relative to this backbone, repeating units having a propylene glycol structure in which the number of repetitions is at least four.

IPC Classes  ?

• C08F 20/06 - Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• C09D 133/04 - Homopolymers or copolymers of esters

Abstract

This carbon dioxide separation/conversion device comprises: one or more separation units (10) for separating carbon dioxide from a carbon dioxide-containing gas to obtain a carbon dioxide-enriched gas; a reaction unit (30) that comprises a catalyst for absorbing and converting carbon dioxide in the carbon dioxide-enriched gas, causes absorption of carbon dioxide in the carbon dioxide-enriched gas by the catalyst, and obtains a post-conversion gas including a conversion product from the carbon dioxide absorbed by the catalyst and hydrogen; and a hydrogen delivery unit (40) that delivers hydrogen to the reaction unit (30), wherein the separation unit (10) comprises one or more separation membrane modules including a separation membrane that separates carbon dioxide from a gas containing carbon dioxide, and a separation membrane module connection unit, which is connected to each separation membrane module and includes a carbon dioxide delivery port through which the carbon dioxide-enriched gas is discharged.

IPC Classes  ?

• C01B 32/40 - Carbon monoxide
• B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
• B01D 53/22 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by diffusion
• B01D 71/70 - Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
• C07C 1/12 - Preparation of hydrocarbons from one or more compounds, none of them being a hydrocarbon from oxides of carbon from carbon dioxide with hydrogen

Abstract

The present invention provides an embryo culture method. More specifically, the invention includes culturing an embryo (especially pre-implantation) on a dish having, on the surface thereof, an extracellular matrix layer having a sufficient thickness. The invention enables, for example, development of an embryo into a post-implantation embryo.

IPC Classes  ?

• C12N 5/073 - Embryonic cells or tissues; Foetal cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms

Abstract

33-R [where R is a hydrogen atom, a chlorine atom, a bromine atom, an iodine atom, or an organic group (which is not a hydrocarbon group)] around the electrical-discharge region in the plasma device; and continuously discharging gases from the plasma device.

IPC Classes  ?

• C07C 17/35 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine

Abstract

22, a hydrogen carbonate, and a carbonate. The membrane-electrode assembly (10) comprises: an electrolytic membrane (13); and a cathode catalyst layer (12) that is provided on the electrolytic membrane (13) and that contains a catalyst. In a state in which the cathode electrode (11) and the cathode catalyst layer (12) are in contact with each other, a cathode contact area, which is an area where the cathode catalyst layer (12) is exposed and where the cathode electrode (11) and the material fluid are not in contact with each other or the cathode electrode (11) and the material fluid are in contact with each other, is smaller than a catalyst contact area, which is an area where the material fluid and an exposure portion in which the cathode catalyst layer is exposed are in contact with each other.

IPC Classes  ?

• C25B 9/65 - Means for supplying current; Electrode connections; Electric inter-cell connections
• C25B 1/23 - Carbon monoxide or syngas
• C25B 9/00 - Cells or assemblies of cells; Constructional parts of cells; Assemblies of constructional parts, e.g. electrode-diaphragm assemblies; Process-related cell features
• C25B 9/23 - Cells comprising dimensionally-stable non-movable electrodes; Assemblies of constructional parts thereof with diaphragms comprising ion-exchange membranes in or on which electrode material is embedded
• C25B 11/037 - Electrodes made of particles

Abstract

The present invention provides a method which comprises: a carbon dioxide application step in which carbon dioxide is applied to an ionic liquid; and a plasma irradiation step in which carbon dioxide is converted into carbon monoxide by irradiating the ionic liquid, to which carbon dioxide has been applied, with a plasma.

IPC Classes  ?

• C01B 32/40 - Carbon monoxide

Abstract

Provided are a cooling device and a cooler that is capable of causing boiling at a low superheat by suppressing an increase in a boiling starting point. The cooler uses a boiling method for cooling a heating element, and comprises: a container that accommodates a working fluid; a cooling member that is provided inside the container so as to face the surface of the heating element and that is composed of a porous body; and at least one metal fine wire or a metal thin film that is provided between the surface of the heating element and the cooling member, and is configured so as to be able to be heated.

IPC Classes  ?

• F28F 13/02 - Arrangements for modifying heat transfer, e.g. increasing, decreasing by influencing fluid boundary
• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

Provided are a cooling member having a favorable cooling effect, a cooler, a cooling device, and a cooling member manufacturing method. The cooling member comprises integrally formed electrolytic metal foils constituted by a double-layer porous material, each layer having different mean pore sizes.

IPC Classes  ?

• H01L 23/427 - Cooling by change of state, e.g. use of heat pipes
• F28D 15/02 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes
• F28D 15/04 - Heat-exchange apparatus with the intermediate heat-transfer medium in closed tubes passing into or through the conduit walls in which the medium condenses and evaporates, e.g. heat-pipes with tubes having a capillary structure
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

This pharmaceutical composition for treatment or prevention of fibrotic disease contains nucleic acid that inhibits the expression of mRNA encoding P4HA3. The fibrotic disease may be at least one disease selected from the group consisting of fibrosis, cirrhosis, renal failure, myocardial infarction, and cancer. The present invention provides a method for preventing or treating fibrotic disease, the method including administering an effective amount of the pharmaceutical composition according to the present invention to a subject who has, or is at risk of contracting, fibrotic disease.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 9/127 - Liposomes
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

This lactic acid bacterium for synthesizing a plasmalogen synthesizes a plasmalogen under an aerobic condition.

IPC Classes  ?

• C12N 1/20 - Bacteria; Culture media therefor
• C12P 9/00 - Preparation of organic compounds containing a metal or atom other than H, N, C, O, S, or halogen

Abstract

Provided is a measurement device for measuring the mass or mass distribution of particles including organic material, said measurement device comprising: a supply means for supplying particles; an irradiation means for irradiating the particles with near infrared light; an imaging means for acquiring data pertaining to the reflectivity of near infrared light reflected from the particles at an m number of specific wavelengths; and a calculation means for calculating the mass of the particles on the basis of the data pertaining to the reflectivity of the near infrared light at the m number of specific wavelengths. Also provided is a measurement method for measuring the mass or mass distribution of particles including organic material, said method comprising the following steps: (a) supplying particles to a measurement device; (b) irradiating the particles with near infrared light and acquiring data pertaining to the reflectivity of near infrared light at an m number of specific wavelengths; and (c) calculating the mass of the particles on the basis of the acquired data.

IPC Classes  ?

• G01N 15/00 - Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
• G01G 9/00 - Methods of, or apparatus for, the determination of weight, not provided for in groups
• G01G 17/00 - Apparatus for, or methods of, weighing material of special form or property
• G01N 21/27 - Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/3563 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light for analysing solids; Preparation of samples therefor
• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light

Abstract

This anticancer drug contains an ATP8B2 inhibitor.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/045 - Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
• A61P 35/00 - Antineoplastic agents
• C12Q 1/06 - Quantitative determination
• G01N 33/15 - Medicinal preparations
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

A computer 30 receives, for a limited document group 4B as a document group of a specific technical field, a setting operation for an annotation in which a main intrinsic representation tag T1 and a sub intrinsic representation tag T2 are associated with each other, generates annotation data 5 (training data), finely tunes a pre-learning model 6, which is learned in advance by using a large document group 3, according to the annotation data 5, and generates an intrinsic representation extraction model 8 for extracting information about intrinsic representations from documents. Furthermore, the computer 30 receives a target document 2 as an analysis target and extracts information about intrinsic representations from the target document 2 by using the specific representation extraction model 8.

IPC Classes  ?

• G06F 40/216 - Parsing using statistical methods
• G06F 40/295 - Named entity recognition

Abstract

This medical coating agent comprises a polymer including a structural unit (A) derived from an ethylenic unsaturated monomer having a urea bond. The polymer contained in the medical coating agent satisfies Condition (i) in a case where a polymer water-holding state when the peak top of heat absorption due to the melting of ice appears at 0°C is defined as a water saturation state in a DSC curve obtained by letting the polymer absorb water and then heating the polymer at a rate of 5°C/min using a differential scanning calorimeter. Condition (i): The intermediate water amount in the water saturation state is not less than 3.0 mass% with respect to the entire amount of the polymer in the water saturation state.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61L 27/34 - Macromolecular materials
• A61L 29/08 - Materials for coatings
• A61L 31/10 - Macromolecular materials
• C08F 20/34 - Esters containing nitrogen

Abstract

Provided are a luminescent material, and an organic EL element using the luminescent material and having a high luminous efficiency and a long lifespan.　Provided is an organic EL element including a luminescent layer between an anode and a cathode that face one another, wherein a compound, which serves as a luminescent dopant and in which a boron atom and a scaffold having a specific structure are combined, is included in at least one luminescent layer. The compound is represented by general formula (1) or general formula (2).

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07F 5/02 - Boron compounds
• H10K 50/00 - Organic light-emitting devices

Abstract

A method for producing an olefin sulfide according to the present invention enables the achievement of a dialkyl polysulfide (A) by reacting an olefin compound (a) represented by formula (1) R1R2C=CHR3(wherein each of R1and R2represents an alkyl group; R3represents a hydrogen atom or an alkyl group; and the total number of carbon atoms in R1, R2and R3 is 2 to 20) and sulfur with each other in the presence of hydrogen.

IPC Classes  ?

• C07C 319/22 - Preparation of thiols, sulfides, hydropolysulfides or polysulfides of hydropolysulfides or polysulfides
• C07B 61/00 - Other general methods
• C07C 321/14 - Sulfides, hydropolysulfides, or polysulfides having thio groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
• C10M 135/04 - Hydrocarbons

Abstract

The purpose of the present invention is to provide a heparin-like substance having a high biological activity (anticoagulant activity) as heparin. Provided is a method for producing a heparin-like substance, the method including a step for culturing an animal cell having, introduced therein, the below-mentioned polynucleotides to produce a supernatant containing the heparin-like substance. A polynucleotide encoding bifunctional heparan sulfate N-deacetylase/N-sulfotransferase (NDST2); a polynucleotide encoding heparan sulfate glucosamine 3-sulfotransferase 1 (Hs3st1); a polynucleotide encoding an extracellular domain of syndecan (SDC); and a polynucleotide encoding 6-O-sulfotransferase.

IPC Classes  ?

• C12N 15/54 - Transferases (2)
• C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin (CIG)
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/12 - Genes encoding animal proteins
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

One of the problems addressed by the present invention is to provide a cancer-cell proliferation inhibitor that contains a compound that is derived from a food component and that is highly safe. The description of the present application discloses a cancer-cell proliferation inhibitor that contains an immune checkpoint inhibitor and at least one of 5-(3,5-dihydroxyphenyl)-γ-valerolactone represented by formula (I), a salt of said compound, and a conjugate of said compound.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61K 31/365 - Lactones
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives

Abstract

This invention includes, e.g., a pharmaceutical composition serving to treat retinitis pigmentosa and containing nanoparticles in which statin is encapsulated.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/10 - Dispersions; Emulsions
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61P 27/02 - Ophthalmic agents

Abstract

An organic semiconductor laser device with a supercell structure composed of a first short-pitch periodic structure with length WS1, a long-pitch periodic structure with length WL and a second short-pitch periodic structure with length WS2 is improved by lengthening (WS1 + WS2), shortening WL, lengthening (WS1 + WL + WS2), or repeating the supercell structure.

IPC Classes  ?

• H01S 5/36 - Structure or shape of the active region; Materials used for the active region comprising organic materials

Abstract

The present invention provides a primer set for detecting the presence of bladder cancer in a specimen, said primer set containing a pair of primers that are oligonucleotides targeting a PLEKHS1 promoter mutation and having a length of 16-21 bases inclusive, and one or more pairs of primers targeting a TERT promoter mutation.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Provided is an electrode material for providing a fuel cell electrode having superior electrode performance and durability.　This electrode material is the following electrode material (A) or electrode material (B). Electrode material (A): An electrode material including a porous composite carrier composed of a carbon carrier made of mesoporous carbon and an electron conductive oxide fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, and including electrode catalyst particles carried on the porous composite carrier, wherein some or all of the electrode catalyst particles are carried on the pore inner surfaces of the mesoporous carbon via the electron conductive oxide. Electrode material (B): An electrode material including a carbon carrier made of mesoporous carbon, and an electrode catalyst composite fixed to, among the pore inner surfaces and pore outer surfaces of the mesoporous carbon, at least the pore inner surfaces of the mesoporous carbon, wherein the electrode catalyst composite includes electrode catalyst particles and an electron conductive oxide, and the electron conductive oxide is present so as to fill the gaps between the electrode catalyst particles.

IPC Classes  ?

• H01M 4/86 - Inert electrodes with catalytic activity, e.g. for fuel cells
• H01M 4/90 - Selection of catalytic material
• H01M 4/92 - Metals of platinum group
• H01M 8/10 - Fuel cells with solid electrolytes

Abstract

11 is an organic group and n is an integer of 2 or larger.

IPC Classes  ?

• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
• C08G 65/10 - Saturated oxiranes characterised by the catalysts used
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation

Abstract

Provided is an ore dressing method that can obtain a low-arsenic-grade concentrate from a high-arsenic-grade starting material.　The ore dressing method has: a repulping step for obtaining a mineral slurry by adding water to a starting material that contains an arsenic-free sulfide mineral, i.e., a sulfide mineral that does not contain arsenic, and an arsenic-containing sulfide mineral, i.e., a copper sulfide mineral that contains arsenic; a pH adjustment step for adjusting the pH of the liquid phase of the mineral slurry to at least 10; a conditioning step for adding an oxidizing agent and an alkali metal xanthate to the mineral slurry; and a flotation step for carrying out flotation using the mineral slurry to effect separation of the starting material into: a floating ore that has a higher grade of arsenic-free sulfide mineral than the starting material, and a sedimented ore that has a higher grade of arsenic-containing sulfide mineral than the starting material. The starting material contains 4.4-5.8 weight parts of arsenic per 100 weight parts of copper.

IPC Classes  ?

• C22B 1/11 - Removing sulfur, phosphorus or arsenic, other than by roasting
• B03D 1/008 - Organic compounds containing oxygen
• B03D 1/012 - Organic compounds containing sulfur
• C22B 1/00 - Preliminary treatment of ores or scrap
• C22B 15/00 - Obtaining copper
• B03D 101/02 - Collectors
• B03D 103/02 - Ores

Abstract

The purpose of the present invention is to provide a novel material that promotes the production of collagen and/or hyaluronic acid and/or activates human epidermal keratinocytes. A lactic acid bacterium belonging to the genus Fructobacillus, a culture of the lactic acid bacterium, a culture supernatant of the lactic acid bacterium, and/or an extract of the lactic acid bacterium are useful as an active ingredient in a collagen production promotor, a hyaluronic acid production promoter, and an epidermal keratinocyte activator.

IPC Classes  ?

• A61K 8/99 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A61K 35/74 - Bacteria
• A61K 35/744 - Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/04 - Drugs for skeletal disorders for non-specific disorders of the connective tissue
• A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
• A61P 27/02 - Ophthalmic agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/08 - Anti-ageing preparations

Abstract

emTTISCRISCRISC is the reverse intersystem crossing rate from the excited triplet state to the excited singlet state.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• H10K 85/30 - Coordination compounds
• H10K 101/20 - Delayed fluorescence emission

Abstract

333, and (8) L-glutamine.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0735 - Embryonic stem cells; Embryonic germ cells

Abstract

Provided is a medical device that can achieve both of biocompatibility and physical properties and contains a polyurethane resin elastomer. The medical device according to an embodiment includes a polyurethane resin elastomer and water contained in the polyurethane resin elastomer. The polyurethane resin elastomer contains polyethylene glycol and a polyisocyanate as constituents thereof, in which the polyethylene glycol has a number average molecular weight of 200 to 2200 inclusive, and the amount of the polyethylene glycol relative to 100% by mass of the constituents of the polyurethane resin elastomer is 1% by mass or more and less than 50% by mass.

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• C08G 18/28 - Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
• C08G 18/44 - Polycarbonates
• C08G 18/48 - Polyethers
• C08G 18/73 - Polyisocyanates or polyisothiocyanates acyclic
• C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
• C08G 18/76 - Polyisocyanates or polyisothiocyanates cyclic aromatic

Abstract

According to the present invention, an epoxy resin composition that is capable of combining flexibility, toughness, and adhesiveness and that can be dismantled easily by heating, a cured product thereof, and a laminate can be provided. The epoxy resin composition of the present invention contains an epoxy resin (A) having an epoxy equivalent of 500-10,000 g/eq, an epoxy resin (B) having an epoxy equivalent of 100-300 g/eq, and a compound (C) having an anthracene dimer skeleton. The epoxy resin (A) is represented by general formula (1), and the compound (C) has two or more epoxy group-containing groups or two or more curable group-containing groups.

IPC Classes  ?

• C08G 59/40 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups characterised by the curing agents used
• B32B 7/12 - Interconnection of layers using interposed adhesives or interposed materials with bonding properties
• B32B 27/38 - Layered products essentially comprising synthetic resin comprising epoxy resins
• C08G 59/20 - Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups characterised by the epoxy compounds used
• C09J 163/00 - Adhesives based on epoxy resins; Adhesives based on derivatives of epoxy resins

Abstract

: The invention provides a sample holder arrangement (1) comprising (i) a 5 collection chamber (100) having an interior space (101), (ii) a sample holding part (3), (iii) an inlet (110), and (iv) an outlet (120); wherein: the inlet (110) is configured for receiving a supercritical fluid (10); the outlet (120) is configured for depressurizing one or more of the interior space (101) and the sample holding part; the sample holding part (3) is detachably configured in the interior space (101); the sample holding part (3) hosts a single crystal of a 0 porous framework (20) such that the single crystal of a porous framework (20) is configured in the interior space (101); and the single crystal of the porous framework (20) is configured in fluid connection with the inlet (110).

IPC Classes  ?

• G01N 23/20025 - Sample holders or supports therefor
• B01D 15/40 - Selective adsorption, e.g. chromatography characterised by the separation mechanism using supercritical fluid as mobile phase or eluent
• G01N 30/84 - Preparation of the fraction to be distributed
• G01N 30/80 - Fraction collectors

Abstract

This compound is represented by formula (I). (In formula (I), a carbon atom in the glycerol backbone may have a substituent; an oxygen atom bound to R1is represented by *; and R1 is formula (I-1) which may have a substituent.)

IPC Classes  ?

• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/661 - Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

PNPLA3PNPLA3) gene. The method can include administering to the subject glutathione (GSH) and/or a nucleic acid molecule encoding a component of the ferroptosis pathway (such as GPX4).

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 39/02 - Antidotes
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• A61K 38/06 - Tripeptides
• A61K 38/44 - Oxidoreductases (1)
• A01N 1/02 - Preservation of living parts

Abstract

This transdermal absorption-type patch is provided with a support and an adhesive agent layer laminated on the support. The adhesive agent layer contains: a solid tacrolimus-surfactant composite in which tacrolimus is covered with a surfactant; an oil phase; and an adhesive agent. The solid tacrolimus-surfactant composite forms solid-in-oil type particles dispersed in the oil phase, and is used for the therapy of neurodegenerative disorders.

IPC Classes  ?

• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 9/66 - Sustained or differential release type containing emulsions, dispersions or solutions
• A61K 9/70 - Web, sheet or filament bases
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical

Abstract

The present invention provides a method for producing 4-hydroxybutyl aldehyde, the method comprising a step in which an allyl alcohol is subjected to a hydroformylation reaction together with a carbon monoxide gas and a hydrogen gas in the presence of a rhodium catalyst and a catalyst that contains at least one bidentate phosphine ligand which is selected from among formulae (1) to (3) (wherein Ar represents an optionally substituted aryl group).

IPC Classes  ?

• C07C 45/50 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with carbon monoxide by oxo-reactions
• B01J 31/24 - Phosphines
• C07B 61/00 - Other general methods
• C07C 47/19 - Saturated compounds having —CHO groups bound to acyclic carbon atoms or to hydrogen containing hydroxy groups
• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Abstract

[Problem] The present invention addresses the problem of providing: a nonlinear optically active copolymer which achieves both high glass transition temperature (Tg) and higher denseness of a nonlinear optical dye; and a nonlinear optical material which is obtained using this copolymer. [Solution] The present invention provides: a nonlinear optically active copolymer which comprises, in the same molecule thereof, at least a repeating unit A of an N-substituted maleimide skeleton represented by formula (1), and a repeating unit B represented by formula (2) and having a nonlinear optically active moiety; and an organic nonlinear optical material, a part of which is composed of this copolymer. [Chemical formula 1] (In the formula, R1represents an alkyl group, an aralkyl group, a cycloalkyl group, an aliphatic crosslinked ring group or an aryl group; R2represents a hydrogen atom or a methyl group; L1represents a divalent hydrocarbon group which may contain an ether bond and/or an ester bond; L2represents *-NHC(=O)O-, *-C(=O)NH- or *-C(=O)O- (wherein * represents a coupling end coupled to L1); and Z represents an atomic group which exhibits nonlinear optical activity.)

IPC Classes  ?

• C08F 222/40 - Imides, e.g. cyclic imides
• C08F 8/30 - Introducing nitrogen atoms or nitrogen-containing groups
• C08F 8/34 - Introducing sulfur atoms or sulfur-containing groups
• C08F 220/10 - Esters
• G02F 1/361 - Organic materials

Abstract

Provided are: a neuron proliferation promoting agent containing, as an active ingredient, an inhibitor of miR-191-5p or an expression inhibitor of miR-191-5p; a prophylactic or therapeutic agent for Alzheimer's disease or depression, the agent containing the neuron proliferation promoting agent; a pharmaceutical composition for promoting neuron proliferation, the composition comprising the neuron proliferation promoting agent and a pharmaceutically acceptable carrier; and a food composition for promoting neuron proliferation, the composition comprising the neuron proliferation promoting agent.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A23L 33/10 - Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
• A61K 31/7024 - Esters of saccharides
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

12121-61212123434344 together form a heterocyclic ring together with a nitrogen atom); n is an integer which is 0, 1, or 2; and m is an integer which is 1 or 0}.

IPC Classes  ?

• A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
• A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 35/00 - Antineoplastic agents
• A61P 37/02 - Immunomodulators
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C07J 9/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/13 - Immunoglobulins

Abstract

The present disclosure describes a bending structure and a method for designing a bending structure with which a thick target member can be folded more compactly.　The bending structure has: a rib base; a first surface support portion which forms a plurality of first surfaces each surrounded by adjacent two first fold lines and a second fold line; a second surface support portion which is provided on the outer side of the first surface with respect to the rib base along the extending direction of the first fold line and which forms a plurality of second surfaces each surrounded by the adjacent two first fold lines and the second fold line; and a base member which has a shape corresponding to the rib base and which is pivotable with respect to the first surface support portion. The bending structure further has a gusset portion in at least a part of a portion between the first surface support portion and the second surface support portion that are arranged along the extending direction of the first fold line, the gusset portion including a surface that pivots with respect to the first surface support portion or the second surface support portion.

IPC Classes  ?

• F16S 1/06 - Sheets, panels, or other members of similar proportions; Constructions comprising assemblies of such members produced by deforming or otherwise working a flat sheet by deforming only

Abstract

This medical coating agent contains a polymer having a structural unit (A) derived from an ethylenic unsaturated monomer having an urethane bond. The polymer contained in the medical coating agent satisfies condition (i) in a case where the polymer water-holding state, when the peak top of heat absorption due to the melting of ice appears at 0°C, is defined as a water saturation state, in a DSC curve obtained by causing the polymer to absorb water and heating the polymer at a rate of 5°C/min using differential scanning calorimeter. Condition (i): The intermediate water amount in the water saturation state is at least 2.0 mass% with respect to the entire amount of the polymer in the water saturation state.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61L 27/34 - Macromolecular materials
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 29/08 - Materials for coatings
• A61L 29/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 31/10 - Macromolecular materials
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

The present invention provides a method whereby carbon dioxide can be efficiently fixed and calcium carbonate, which is a valuable, can be efficiently produced from the carbon dioxide, and whereby waste gypsum boards can be effectively utilized for fixing carbon dioxide without being discarded. This method comprises a first step, in which a first solution, which contains an alkali metal hydroxide, is brought into contact with a gas including carbon dioxide to thereby yield a second solution, which contains an alkali metal salt, and a second step, in which the second solution is brought into contact with a gypsum-containing substance to thereby yield calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B01D 53/62 - Carbon oxides
• B01D 53/75 - Multi-step processes
• B01D 53/78 - Liquid phase processes with gas-liquid contact

Abstract

Provided is an insulated wire that comprises an insulating coating that: is formed from a material that includes a silicone resin; and has high oil resistance. Also provided are: a wire harness that includes such an insulated wire; and a production method for such an insulated wire.　An insulated wire 1 includes a wire conductor 2 and an insulating coating 3 that is a crosslinked polymer material and coats the outer circumference of the wire conductor 2. The crosslinked polymer material includes a metal ion and a silicone resin that has a side chain that includes a substituent that can form an ionic bond with the metal ion, the silicone resin being crosslinked by ionic bonding between the metal ion and the substituent. The insulated wire 1 is produced by applying a crosslinkable polymer composition that contains a metal compound that releases the metal ion when heated and the silicone resin to the outer circumference of the wire conductor 2 and heating to crosslink the crosslinkable polymer composition and form the insulating coating 3 of the crosslinked polymer material.

IPC Classes  ?

• H01B 7/02 - Disposition of insulation
• C08G 77/382 - Polysiloxanes modified by chemical after-treatment containing atoms other than carbon, hydrogen, oxygen or silicon
• C08J 3/24 - Crosslinking, e.g. vulcanising, of macromolecules
• C08K 5/057 - Metal alcoholates
• C08K 5/07 - Aldehydes; Ketones
• C08L 83/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 13/14 - Insulating conductors or cables by extrusion

Abstract

This medical coating agent contains a polymer including a structural unit (A) derived from an ethylenically unsaturated monomer having a urethane bond. In a DSC curve obtained by including water into the polymer and increasing the temperature using a differential scanning calorimeter (DSC) at a rate of 5°C/min, the glass transition temperature of the polymer in a water saturated state is -25°C or lower, when the water saturated state is defined as the water-containing state of the polymer in which the peak top of an endothermic process caused by melting of ice appears at 0°C.

IPC Classes  ?

• A61L 33/06 - Use of macromolecular materials
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61L 27/34 - Macromolecular materials
• A61L 27/40 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 27/50 - Materials characterised by their function or physical properties
• A61L 29/08 - Materials for coatings
• A61L 29/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 29/14 - Materials characterised by their function or physical properties
• A61L 31/10 - Macromolecular materials
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

Provided are an expression promoting agent for a mental health-related gene that can be expected to promote mental health, especially ameliorate major neurocognitive disorder, and a functional food for mental health promotion. This expression promoting agent for a mental health-related gene contains, as a major ingredient for triggering the function, dipeptides represented by Gly-Pro and/or Leu-Pro. The expression promoting agent is also characterized in that the mental health-related gene is a brain-derived neurotrophic factor gene. This functional food for mental health promotion contains, as a major ingredient for triggering the function, dipeptides represented by Gly-Pro and/or Leu-Pro.

IPC Classes  ?

• A23L 33/18 - Peptides; Protein hydrolysates
• A61K 8/64 - Proteins; Peptides; Derivatives or degradation products thereof
• A61K 38/05 - Dipeptides
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/20 - Hypnotics; Sedatives
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61Q 1/00 - Make-up preparations; Body powders; Preparations for removing make-up
• A61Q 5/04 - Preparations for permanent waving or straightening the hair
• A61Q 5/10 - Preparations for permanently dyeing the hair
• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastes; Mouth rinses
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/10 - Washing or bathing preparations

Abstract

This heavy-metal-free photon upconversion composition that includes a compound having a coumarin skeleton exhibits high photon upconversion efficiency at low excitation light intensity.

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• G02B 5/20 - Filters

Abstract

In a magnetic attraction unit (1A), a permanent magnet (3), a rod (4), and a cam follower (5) are supported by a frame (2), which abuts an attachment surface (S), so as to be able to advance and retreat with respect to the attachment surface (S). A cam (6) is provided with a cam surface (6b) which abuts the cam follower (5) from the attachment surface (S) side, and is supported by the frame (2) so as to be able to slide or rotate. When the cam (6) slides or rotates, the cam surface (6b) causes the cam follower (5) to advance and retreat with respect to the attachment surface (S). An elastic member (7) applies elastic force (Fs) in a direction such that the cam follower (5) and the cam (6) abut each other. The cam surface (6b) is designed to have a shape such that, on the basis of first data which indicates attachment force (Fm) with respect to the distance between the attachment surface (S) and the permanent magnet (3) and second data which indicates the elastic force (Fs) with respect to the displacement of the elastic member (7), the attachment force (Fm) and the elastic force (Fs) are balanced in directions orthogonal to the cam surface (6b).

IPC Classes  ?

• H01F 7/02 - Permanent magnets
• B63B 59/06 - Cleaning devices for hulls

Abstract

The present invention provides a trisulfide-compound-containing agent for inhibiting nitration of tyrosine residues in hepatocyte growth factor, the trisulfide compound being: glutathione trisulfide or a pharmaceutically acceptable salt thereof; or a compound represented by formula (1) (wherein X represents -OR1or -NR2R3, R1represents a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, R2and R3 independently represent a hydrogen atom or an alkyl group containing 1 to 6 carbon atoms, and the alkyl group may have one or more substituents selected from the group consisting of amino groups and carboxy groups), a pharmaceutically acceptable salt thereof, or a cyclodextrin clathrate thereof.

IPC Classes  ?

• A61K 31/385 - Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
• A61K 38/06 - Tripeptides
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Provided is a deuterium-enriched composition comprising a deuterium-substituted carboxylic acid or a salt thereof, wherein the carboxylic acid or the salt thereof includes an α hydrogen of a carboxy group and a hydrogen other than the α hydrogen bonded to a carbon, the deuterium substitution rate of the α hydrogen is not less than 5%, the deuterium substitution rate of the hydrogen other than the α hydrogen is not more than 3%, and when the carboxylic acid or the salt thereof comprises, in the molecule thereof, a group having a carbonyl group other than the carboxy group, the α hydrogen of the carbonyl group is not included in hydrogen other than the α hydrogen.

IPC Classes  ?

• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• C07C 57/02 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
• C07C 57/38 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings polycyclic
• C07C 59/13 - Saturated compounds having only one carboxyl group and containing ether groups, groups, groups, or groups containing rings
• C07C 59/205 - Saturated compounds having only one carboxyl group and containing keto groups containing rings
• C07C 59/70 - Ethers of hydroxy-acetic acid
• C07C 59/84 - Unsaturated compounds containing keto groups containing six-membered aromatic rings
• C07C 61/135 - Saturated polycyclic compounds having a carboxyl group bound to a condensed ring system having three rings
• C07C 61/29 - Unsaturated compounds polycyclic having a carboxyl group bound to a condensed ring system
• C07C 69/14 - Acetic acid esters of monohydroxylic compounds
• C07C 69/44 - Adipic acid esters
• C07C 229/42 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
• C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
• C07C 317/44 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
• C07C 323/62 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
• C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
• C07D 207/337 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 209/28 - 1-(4-Chlorobenzoyl)-2-methyl- indolyl-3-acetic acid, substituted in position 5 by an oxygen or nitrogen atom; Esters thereof
• C07D 209/48 - Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
• C07D 231/56 - Benzopyrazoles; Hydrogenated benzopyrazoles
• C07D 263/32 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• C07D 313/12 - [b, e]-condensed
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered

Abstract

The present invention provides an osteoarthritis progression inhibitor containing, as active ingredients, a G-protein-coupled receptor kinase 5 inhibitor and hyaluronic acid or a pharmaceutically acceptable salt thereof. The G-protein-coupled receptor kinase 5 inhibitor may be amlexanox. The osteoarthritis progression inhibitor may be administered by intra-articular injection. The present invention provides an osteoarthritis progression inhibition kit containing a G-protein-coupled receptor kinase 5 inhibitor and hyaluronic acid or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/728 - Hyaluronic acid
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

Provided are: a cross-linkable polymer composition for providing a cross-linked body that is capable of realizing both heat resistance and re-moldability; a cross-linked polymer material that is capable of realizing both heat resistance and re-moldability; an insulated wire comprising such a cross-linked polymer material, and a wire harness.　The present invention provides a cross-linkable polymer composition comprising a component A in which metal ions are freed by heat, and a component B configured from an organic polymer having a side chain, wherein: the component B includes, in the side chain, an electron-accepting substituent which is capable of forming an ionic bond with a metal ion freed from the component A; and a cross-linked body in which the component B is cross-linked by the metal ion freed from the component A has a flow starting temperature in the range of 190°C to 300°C. Further, the present invention provides a cross-linked polymer material comprising a cross-linked body of the cross-linking polymer composition. The present invention also provides: an insulated wire having a wire conducting body and an insulation covering which is configured from the cross-linked polymer material and covers the outer periphery of the wire conducting body; and a wire harness comprising the insulated wire.

IPC Classes  ?

• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
• C08K 5/07 - Aldehydes; Ketones
• C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation
• H01B 7/08 - Flat or ribbon cables

Abstract

The present invention provides: a crosslinkable polymer composition which enables the achievement of a crosslinked body that has both heat resistance and re-formability, while exhibiting high wear resistance; a crosslinked polymer material which has both heat resistance and re-formability, while exhibiting high wear resistance; and an insulated wire and a wiring harness, each of which comprises this crosslinked polymer material.　The present invention provides a crosslinkable polymer composition which contains a component A that releases metal ions by means of heat and a component B that is composed of an organic polymer having a side chain and a Shore D hardness of 50 or more, wherein: the component B comprises, in the side chain, an electron-withdrawing substituent that is capable of forming an ion bond with a metal ion that is released from the component A; and a crosslinked body, which is obtained by crosslinking the component B by means of metal ions that are released from the component A, has a flow starting temperature within the range from 190°C to 300°C. The present invention also provides a crosslinked polymer material which comprises a crosslinked body of the crosslinkable polymer composition.

IPC Classes  ?

• C08L 101/02 - Compositions of unspecified macromolecular compounds characterised by the presence of specified groups
• C08K 5/07 - Aldehydes; Ketones
• C08L 23/26 - Compositions of homopolymers or copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond; Compositions of derivatives of such polymers modified by chemical after-treatment
• H01B 7/00 - Insulated conductors or cables characterised by their form
• H01B 7/02 - Disposition of insulation
• H01B 7/08 - Flat or ribbon cables

Abstract

Provided are a calcium carbonate generation method and a system that make it possible to use calcium-containing waste to generate high-purity calcium carbonate.　According to the present invention, a calcium carbonate generation method that generates calcium carbonate from calcium-containing waste is characterized by having a calcium dissolution step for adding aqueous hydrochloric acid to the calcium-containing waste to dissolve the calcium and generate an aqueous solution that includes calcium ions, a separation step for adjusting a hydrogen ion concentration index for the aqueous solution that includes the calcium ions and separating a component that includes at least one substance selected from the group that consists of Si, Al, Mg, and heavy metals from the aqueous solution, and a calcium carbonate recovery step for using the aqueous solution obtained via the separation step and an aqueous solution that includes potassium carbonate and/or sodium carbonate to generate calcium carbonate.

IPC Classes  ?

• C01F 11/18 - Carbonates
• B09B 3/70 - Chemical treatment, e.g. pH adjustment or oxidation
• C01D 7/32 - Purification by dialysis
• C04B 7/60 - Methods for eliminating alkali metals or compounds thereof

Abstract

The present invention provides a novel compound which exhibits an excellent anti-inflammatory effect and which is formed from a compound represented by general formula (I), a racemate thereof, or salts of the compound and the racemate. (In general formula (I), X represents an oxygen atom, a nitrogen atom, or a sulfur atom; R1represents an unsaturated aliphatic hydrocarbon group; R2represents a saturated or unsaturated aliphatic hydrocarbon group; and R3 represents choline, ethanolamine, inositol, or serine.)

IPC Classes  ?

• C07F 9/09 - Esters of phosphoric acids
• C07F 9/10 - Phosphatides, e.g. lecithin
• A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

11 is a group represented by formula (AA); Y is a group represented by formula (BB); and X is a covalent substituent represented by formula (CC)], a pharmaceutically acceptable salt or solvate thereof, or a prodrug of the same.

IPC Classes  ?

• C07C 243/34 - Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of a carbon skeleton further substituted by nitrogen atoms
• A61K 9/08 - Solutions
• A61K 31/16 - Amides, e.g. hydroxamic acids
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/4015 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/422 - Oxazoles not condensed and containing further heterocyclic rings
• A61K 38/05 - Dipeptides
• A61P 31/12 - Antivirals
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/20 - Antivirals for DNA viruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07D 209/42 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention addresses the problem of providing a novel polymer composition which takes advantage of a bioaffinity attributable to the structure of 2-pyrrolidone, especially providing a polymer composition which, due to the inclusion of a novel structure including said 2-pyrrolidone structure, is water-insoluble.　The polymer composition includes a polymer comprising a given monomer unit having the structure of 2-pyrrolidone in a side chain, and is water-insoluble over a temperature region within the range of 0-100°C.

IPC Classes  ?

• C08F 20/18 - Esters of monohydric alcohols or phenols of phenols or of alcohols containing two or more carbon atoms with acrylic or methacrylic acids

Abstract

Provided are: a gold ore pretreatment method capable of facilitating recovery of gold even when a gold ore contains a sulfide or a carbonaceous component; and a gold recovery method exhibiting a high gold recovery rate. The pretreatment method includes a biological oxidation step in which a gold ore containing a sulfide and iron-oxidizing bacteria are brought into contact with each other and held for a prescribed time. The gold recovery method includes: a pretreatment step for applying pretreatment to a gold ore by means of a pretreatment method; a leaching step for leaching gold from the gold ore to obtain a leachate; an adsorption step for allowing activated carbon to adsorb gold in the leachate; and an elution step for eluting gold from the activated carbon to obtain a gold solution. Because the sulfide enclosing gold particles is oxidatively decomposed by the action of the iron-oxidizing bacteria, the gold particles are liberated, whereby gold recovery is facilitated. As a result, the gold recovery rate can be increased.

IPC Classes  ?

• C22B 11/00 - Obtaining noble metals
• C22B 1/00 - Preliminary treatment of ores or scrap
• C22B 3/04 - Extraction of metal compounds from ores or concentrates by wet processes by leaching
• C22B 3/18 - Extraction of metal compounds from ores or concentrates by wet processes with the aid of microorganisms or enzymes, e.g. bacteria or algae
• C22B 3/24 - Treatment or purification of solutions, e.g. obtained by leaching by physical processes, e.g. by filtration, by magnetic means by adsorption on solid substances, e.g. by extraction with solid resins

Abstract

A metal recovery device including a leaching unit for causing a metal element contained in a composition to directly leach into a hydrophobic deep eutectic solvent and a recovery unit for recovering the metal element by separating the metal element from the deep eutectic solvent, wherein the metal element-containing composition is solid at 25 ˚C and does not contain any inorganic acid, the metal element is formed from a metal, a metal compound, or metal ions, and　the deep eutectic solvent does not contain any inorganic acid.

IPC Classes  ?

• C22B 3/16 - Extraction of metal compounds from ores or concentrates by wet processes by leaching in organic solutions
• C22B 3/02 - Apparatus therefor
• C22B 3/20 - Treatment or purification of solutions, e.g. obtained by leaching
• C22B 7/00 - Working-up raw materials other than ores, e.g. scrap, to produce non-ferrous metals or compounds thereof
• C22B 23/06 - Refining
• C22B 26/12 - Obtaining lithium

Abstract

[Problem] To provide a superconductive cable which is capable of storing magnetic energy while performing electric power transmission between a power source having an output that fluctuates over a short time period, and a load, and which is capable of significantly increasing the amount of energy that can be stored, by causing mutual inductance to act between an outward superconductive line and a return superconductive line. [Solution] A superconductive cable 12 for performing electric power transmission between a power source 11 having an output that changes over time, and a load 13, is provided with an energy storing means including: a first superconductive wire 12a which is connected between a positive electrode side of the power source 11 and the load 13, and which is wound in a helical shape with a prescribed angle with respect to the longitudinal direction of a core material 14 comprising a non-magnetic body; and a second superconductive wire 12b which is connected between a negative electrode side of the power source 11 and the load 13, is wound in a stacked manner onto the core material 14, so as to be insulated from the first superconductive wire 12a, and which is wound in a helical shape with a prescribed angle with respect to the longitudinal direction of the core material 14, so as to generate a magnetic field in the same direction as a magnetic field that arises when a current flows through the first superconductive wire 12a.

IPC Classes  ?

• H01B 12/02 - Superconductive or hyperconductive conductors, cables or transmission lines characterised by their form
• H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
• H02J 15/00 - Systems for storing electric energy

Abstract

This brain activity estimation method comprises: a preliminary preparation step of preliminarily acquiring a source estimation matrix for use in source estimation on the basis of brain waves or a magnetoencephalogram of a subject acquired for the preliminary preparation; and a feature amount calculation step of calculating a feature amount relating to the brain activity of the subject by applying the source estimation matrix to brain activity measurement information based on the brain waves or magnetoencephalogram of the subject acquired for measurement, and further performing a time-frequency analysis.

IPC Classes  ?

• A61B 5/374 - Detecting the frequency distribution of signals, e.g. detecting delta, theta, alpha, beta or gamma waves
• A61B 5/245 - Detecting biomagnetic fields, e.g. magnetic fields produced by bioelectric currents specially adapted for magnetoencephalographic [MEG] signals

Abstract

This image generation processing device comprises: an intersection point set generation unit that acquires an intersection point set from the connection relationship among intersection points of laser lines detected in each frame of a video which is a group of successive frames imaged by an imaging means which is obtained by integrating and movably fixing a camera for imaging a target area during a specific period and a plurality of plane-crossing laser oscillation units for projecting plane-crossing laser beams onto a substance in the target area and from tracking results of the intersection points of the laser lines detected in the successive frames; a simultaneous equation generation unit that, on the basis of the fact that the intersection points in the intersection point set are on two laser planes formed by the plane-crossing laser beams, generates simultaneous equations by serially obtaining a plurality of constraint equations and satisfying the constraint equations simultaneously; a three-dimensional position estimation unit that reconstructs, in a projection space, three-dimensional coordinates of a laser plane by solving the simultaneous equations; and a three-dimension reconstruction unit that reconstructs, in the projection space, three-dimensional coordinates of laser line reflection positions by an optical cutting method using the estimated three-dimensional coordinates of the laser plane and the laser lines detected in each frame of the video.

IPC Classes  ?

• G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
• G06T 7/55 - Depth or shape recovery from multiple images

Abstract

In this percutaneous absorption agent, an ionic liquid is finely dispersed in an oil phase, the ionic liquid including a hydrophilic peptide drug, choline, and carboxylate ions obtained by dissociation of hydrogen ions from carboxy groups of a fatty acid. The average particle diameter of the ionic liquid finely dispersed in the oil phase may be 1-100 nm. The centers of particles of the ionic liquid finely dispersed in the oil phase may comprise the hydrophilic peptide drug and one or more selected from the group consisting of choline propionate, choline lactate, and choline formate. The hydrophilic peptide drug may be insulin. The fatty acid may be oleic acid or linoleic acid. The percutaneous absorption agent may further include sorbitan monolaurate in the oil phase.

IPC Classes  ?

• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 9/10 - Dispersions; Emulsions
• A61K 38/02 - Peptides of undefined number of amino acids; Derivatives thereof
• A61K 38/28 - Insulins
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/18 - Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Abstract

Provided are: a compound represented by formula (II); a luminescent material containing this compound; and a luminescent element containing this luminescent material. (In formula (II), R1, R2, R3, R4, R5, R6, R7and R8 are each independently a straight chain or branched chain alkyl group having 1-4 carbon atoms, m values are each independently an integer between 0 and 5, and n values are each independently an integer between 0 and 4.)

IPC Classes  ?

• C09K 11/06 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing organic luminescent materials
• C07F 5/02 - Boron compounds
• H01L 51/50 - Solid state devices using organic materials as the active part, or using a combination of organic materials with other materials as the active part; Processes or apparatus specially adapted for the manufacture or treatment of such devices, or of parts thereof specially adapted for light emission, e.g. organic light emitting diodes (OLED) or polymer light emitting devices (PLED)

Abstract

A probe that comprises a sequence that comprises a base sequence that does not hybridize to mammalian nucleic acids under stringent conditions and includes a base sequence indicted by any of SEQ ID Nos 1-673. A probe set is provided that comprises at least two types of the probe. The at least two types of probe do not hybridize with each other under stringent conditions.

IPC Classes  ?

• C12N 15/09 - Recombinant DNA-technology
• C12Q 1/6813 - Hybridisation assays
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

Provided is a novel polymer composition exhibiting osmoregulatory activity. Provided particularly is an osmolyte which can inhibit protein alteration, etc. in lower concentrations.　This osmoregulator is characterized by comprising a polymer composition including a polymer main chain and a side chain bonded thereto which has a constituent unit comprising an amine oxide structure.

IPC Classes  ?

• C08F 20/56 - Acrylamide; Methacrylamide
• C07K 2/00 - Peptides of undefined number of amino acids; Derivatives thereof
• C07K 14/415 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
• C12N 1/04 - Preserving or maintaining viable microorganisms
• C12N 5/09 - Tumour cells

Abstract

1132926333279412331622 particles. This hydrogen embrittlement prevention agent for an aluminum alloy material can effectively prevent or suppress hydrogen embrittlement.

IPC Classes  ?

• C22C 1/02 - Making non-ferrous alloys by melting
• B22F 1/00 - Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
• C22C 21/00 - Alloys based on aluminium
• C22C 21/10 - Alloys based on aluminium with zinc as the next major constituent
• C22F 1/00 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working
• C22F 1/053 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of aluminium or alloys based thereon of alloys with zinc as the next major constituent

Abstract

This carbon monoxide gas sensor 10 is a single chamber sensor for measuring the concentration of gaseous-phase carbon monoxide gas. The carbon monoxide gas sensor 10 has electrodes 12, 13 respectively arranged on the two surfaces of a solid electrolyte layer 11. One electrode among the electrodes is active for oxidization of carbon monoxide gas and the other electrode among the electrodes is less active for oxidization of carbon monoxide gas than the one electrode. The carbon monoxide gas sensor 10 is configured to measure a short circuit current between the electrodes. In the carbon monoxide gas sensor 10, the solid electrolyte layer has oxide ion conductivity.

IPC Classes  ?

• G01N 27/407 - Cells and probes with solid electrolytes for investigating or analysing gases
• G01N 27/416 - Systems

Abstract

The purpose of the present invention is to provide medical therapy for treating and/or preventing Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, for which radical treatments have not yet been discovered.　The present invention pertains to a pharmaceutical composition for preventing or treating Rett syndrome (RTT), autism spectrum disorders, or schizophrenia, the pharmaceutical composition comprising a reverse transcriptase inhibitor of retrotransposon L1.

IPC Classes  ?

• A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/18 - Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 31/513 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine

Abstract

[Problem] To provide a thermoelectric element, a power generation device, an electronic apparatus, and a method for manufacturing the thermoelectric element with which power generation efficiency can be stabilized. [Solution] A thermoelectric element 1 which does not require a temperature difference between electrodes, the thermoelectric element comprising: a first electrode 11; a second electrode 12 that is provided spaced apart from the first electrode 11; a donor layer 21 that is provided between the first electrode 11 and the second electrode 12, and that comprises at least one layer; and an acceptor layer 22 that is provided between the donor layer 21 and the second electrode 12, and that includes at least one layer. The thermoelectric element is characterized in that the donor layer 21 and/or the acceptor layer 22 contain an organic substance exhibiting orientational polarization.

IPC Classes  ?

• H02N 11/00 - Generators or motors not provided for elsewhere; Alleged perpetua mobilia obtained by electric or magnetic means
• H01L 37/00 - Thermoelectric devices without a junction of dissimilar materials; Thermomagnetic devices, e.g. using Nernst-Ettinghausen effect; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof